PERSISTENT ACTIVE INFECTION OF EPSTEIN-BARR VIRUS (EBV) IN CARRIER FEMALES OF THE X-LINKED LYMPHOPROLIFERATIVE SYNDROME (XLP) NLM AIDSLINE Important note: Information in this article was accurate in 1982. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


PERSISTENT ACTIVE INFECTION OF EPSTEIN-BARR VIRUS (EBV) IN CARRIER FEMALES OF THE X-LINKED LYMPHOPROLIFERATIVE SYNDROME (XLP)

Int Congr Ser; 571:375-379 1982. Unique Identifier : AIDSLINE ICDB/82625235
Sakamoto K; Seeley JK; Purtilo DT; Second Dept. Surgery, Kumamoto Univ. Medical Sch., Kumamoto 860,; Japan

Abstract: Among conditions that may follow infection with Epstein-Barr virus (EBV), is malignant lymphoma in males affected by the X-linked lymphoproliferative syndrome (XLP). To test the hypothesis that the variable expression of XLP is manifested in obligate carrier females, blood from 12 obligate carrier females was studied for anti-viral capsid antigen (VCA), anti-early antigen (anti-EA) and anti-Epstein-Barr nuclear-associated antigen (EBNA). All carriers were seropositive to EBV. The reciprocal geometric mean titer for IgG anti-VCA was elevated to 570 in the carrier females compared to 100 in 24 controls. The range of anti-VCA was from 80 to 5,120. IgA class anti-VCA was found in 2/3 of the carriers. All but one of those with anti-VCA of IgA class showed anti-EA, indicative of active infection and immunodeficiency. About one-half of the carriers had persistent anti-EA antibodies. However, the anti-EBNA levels of carrier females were similar to those of the healthy controls. There was no apparent relationship between IgM level and EBV-specific antibody titers. The paradoxically elevated EBV-specific antibodies which tend to persist in obligate carriers of XLP provides an opportunity to define the immunopathology of XLP and to detect carrier females. (17 Refs)
Keywords: Antibodies, Viral/IMMUNOLOGY Antigens, Viral/IMMUNOLOGY Capsid/IMMUNOLOGY *Carrier State Female Herpesvirus 4, Human/*IMMUNOLOGY Human Infectious Mononucleosis/*ETIOLOGY Lymphoma/*ETIOLOGY Lymphoproliferative Disorders/COMPLICATIONS/*GENETICS/IMMUNOLOGY *X Chromosome MEETING PAPER

KWDantibodies,viral/immunologyantigens,viral/immunologycapsid/immunologyKWDcarrierstatefemaleherpesvirus4,human/KWDimmunologyhumaninfectiousmononucleosis/KWDetiologylymphoma/KWDetiologylymphoproliferativedisorders/complications/KWDgenetics/immunologyKWDxchromosomemeetingpaper
821030
M82A0023

Copyright © 1982 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1982. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1982. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .